SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
CONTACT: Contact: Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1-314-368-5189
TOKYO, Feb. 2, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a…
TAMPA, Fla., Feb. 2, 2026 /PRNewswire/ -- Happy Panda announces its official market launch with a…
GARDENA, Calif., Feb. 2, 2026 /PRNewswire/ -- FUGO Precision 3D, developer of the world's first all-in-one…
OXNARD, CA / ACCESS Newswire / February 2, 2026 / Quality Dental Services functions as…
Seminar offers step-by-step blueprint to grow your clinic, build passive income, and regain personal timeOTTAWA,…
BOSTON, Feb. 2, 2026 /PRNewswire/ -- Aura, a leading AI-powered online safety platform for families,…